title: Anti-herpes virus activity of polyether antibiotic CP-44161 in vivo.
abstract: In the previous study, we discovered a polyether antibiotic CP-44161, which was reported earlier as an anticoccidal agent, as an anti-varicella zoster virus compound. In this study, we demonstrated that CP-44161 had a very strong and broad anti-herpes virus activities against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. To determine the antiviral activity of CP-44161 in vivo, we examined its effect on the cutaneous HSV-2 infection model in Balb/c mice. CP-44161 showed inhibitory effect on lesion development as well as acyclovir (ACV) when the treatment was started from day 3. Meanwhile, in case the start of treatment was delayed until day 4, when ACV was no longer effective, the effectiveness of CP-44161 still remained. In this model, CP-44161 also showed inhibitory effect on the proliferation of HSV-2 DNA in dorsal root ganglia. This is the first article to report that polyether antibiotics can be effective on viral infection in vivo.
authors.affiliation: Fermentation Research Labs, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan. yukiko.yamagishi@jp.astellas.com
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamagishi
authors.forename: Motoi
authors.initials: M
authors.lastname: Ueno
authors.forename: Chihoko
authors.initials: C
authors.lastname: Ueno
authors.forename: Akemi
authors.initials: A
authors.lastname: Kato
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kanasaki
authors.forename: Bunji
authors.initials: B
authors.lastname: Sato
authors.forename: Koji
authors.initials: K
authors.lastname: Takakura
authors.forename: Akihiko
authors.initials: A
authors.lastname: Fujie
authors.forename: Hidenori
authors.initials: H
authors.lastname: Nakajima
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujii
authors.forename: Motohiro
authors.initials: M
authors.lastname: Hino
authors.forename: Eisaku
authors.initials: E
authors.lastname: Tsujii
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds; D002236:Carbohydrate Conformation; D002240:Carbohydrate Sequence; D002470:Cell Survival / Q000187:drug effects; D002522:Chlorocebus aethiops; D004279:DNA, Viral / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D004987:Ethers; D005260:Female; D005663:Furans / Q000494:pharmacology* / Q000627:therapeutic use*; D005727:Ganglia, Spinal / Q000737:chemistry / Q000821:virology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D018258:Herpesvirus 2, Human / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D011714:Pyrans / Q000494:pharmacology* / Q000627:therapeutic use*; D014709:Vero Cells
chemical_list: D000998:Antiviral Agents; D001952:Bridged-Ring Compounds; C425408:CP44,161; D004279:DNA, Viral; D004987:Ethers; D005663:Furans; D011714:Pyrans; D000212:Acyclovir